Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation

• Autor(a) principal: Gonçalves-Reis, Maria
• Data de Publicação: 2024
• Outros Autores: Proença, Daniela, Frazão, Laura P., Neto, João L., Silva, Sílvia, Pinto-Marques, Hugo, Pereira-Leal, José B., Cardoso, Joana
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/163817
• topic: Analytical validation; Hepatocellular carcinoma; HepatoPredict; Liver transplantation; Multi-target genomic assay; Prognostic; Radiological and Ultrasound Technology; Clinical Biochemistry

Funding Information: The authors wish to thank to the European Innovation Council for having partially financed this work with a grant under the EIC Accelerator scheme (Contract Nº946364). The authors also thank the patients, Neuralshift, and the pathology team from the Curry Cabral Hospital headed by António Figueiredo, with a special mention to Clara Rodrigues. Moreover, the authors particularly acknowledge the Biobank IRBLleida (PT20/00021) integrated in the Spanish National Biobanks Network and Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncología Catalunya ( XBTC ), as well as the Biobank ISABIAL integrated in the Spanish National Biobanks Network and in the Valencia Biobanking Network for their collaboration. Funding Information: This work was supported by the EU EIC Innovation Council ( EIC accelerator grant GA No 946364). Funding Information: Samples: In this study, HCC samples preserved as FFPE tissue were used. FFPE HCC samples were acquired from four different suppliers: Biobank IRBLleida (PT20/00021), integrated in the Spanish National Biobanks Network and Xarxa de Bancs de Tumors de Catalunya (XBTC) sponsored by Pla Director d'Oncología de Catalunya; Biobank ISABIAL, integrated in the Spanish National Biobanks Network and in the Valencian Biobanking Network; and biorepositories from Amsbio (US) and Biotech (US). All samples were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committees. Moreover, clinical samples from a retrospective clinical study approved by the ethics authorities and taking place in the Curry Cabral Hospital (Lisbon, Portugal), were also used. All HCC FFPE samples were acquired either sectioned with 3–5 μm thickness or as paraffin blocks that were then cut in 3–5 μm thick slices using a microtome (Leica SM2010R Sliding Microtome, Leica Biosystems) and mounted on a glass slide.This work was supported by the EU EIC Innovation Council (EIC accelerator grant GA No 946364).The authors wish to thank to the European Innovation Council for having partially financed this work with a grant under the EIC Accelerator scheme (Contract Nº946364). The authors also thank the patients, Neuralshift, and the pathology team from the Curry Cabral Hospital headed by António Figueiredo, with a special mention to Clara Rodrigues. Moreover, the authors particularly acknowledge the Biobank IRBLleida (PT20/00021) integrated in the Spanish National Biobanks Network and Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d'Oncología Catalunya (XBTC), as well as the Biobank ISABIAL integrated in the Spanish National Biobanks Network and in the Valencia Biobanking Network for their collaboration. Publisher Copyright: © 2024 Ophiomics